Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=811 An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Phase 3 N=939 A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Overall Survival — 12.55; 13.40 months — p=0.94896
Phase 2 N=25 Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Primary: Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments — 100; 66; 100; NA Percent Accuracy
Phase 3 N=633 First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.3; 11.5 Months — p=0.9561
Phase 4 N=109 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods — 5.6 months
Phase 2 N=46 Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 77.1 percentage of participants
Phase 2 N=42 Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Lung Cancer
Primary: PERCIST Partial Metabolic Response — 6 participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=172 A Study in Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Progression-free Survival (PFS) — 5.45; 5.22 months — p=0.848
Phase 3 N=1,093 First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.5; 9.9 Months — p=0.0120
Phase 2 N=54 A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Primary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) — 51.0 percentage of…
Phase 2 N=76 A Study in Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Phase 2: Progression-Free Survival Time — 4.7; 1.5 months
N/A N=76 National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC
Non-small Cell Lung Cancer
Primary: Percentage of Participants Reporting Quality of Care on Selected National Comprehensive Cancer Center (NCCN) Recommendations — 80; 0; 50; 28.6 percentage of participants
Phase 2 N=35 Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer · Lung Cancer, Non-Small Cell
Primary: Number of Participants Achieving Tumor Shrinkage Based on Change in Tumor Volume — 2; 33 participants
Phase 2 N=71 Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Phase 2 N=38 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Phase 2 N=30 Molecular Profiling in Lung Cancer Patients
Non-Small Cell Lung Cancer · Carcinoma
Primary: High/Low Expression of Selected Molecular Markers in Tumor Tissues and Hypermethylated Genes in Peripheral Blood
Phase 2 N=52 Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
Lung Cancer
Primary: Disease Response - Radiographic — 1; 16 participants
Phase 2 N=28 Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)
Advanced Non-small Cell Lung Cancer
Primary: Best Overall Response (BOR) — 2; 2; 9; 1 Participants
N/A N=200 A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Squamous Non-small Cell Lung Cancer
Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months
Phase 2 N=20 Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung · Non-Small Cell Lung Cancer · Nonsmall Cell Lung Cancer
Primary: Response Rate (RR) — 3 Participants
Phase 2 N=69 Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
Non-Small-Cell Lung Cancer
Primary: Median Time to Progression (TTP) — 6.11 months
Phase 2 N=44 A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer Metastatic
Primary: Objective Response Rate (ORR) — 32.5 percentage of participants
Phase 3 N=572 A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) in the TC3 or IC3-WT Populations — 13.1; 20.2 Months — p=0.0106
Phase 2 N=247 A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 7.4; 3.8; 4.4 months — p=0.003
Phase 2 N=24 Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Primary: Percentage of Subjects With Detectable Circulating T Cells After Treatment — 16.7 Percentage of participants
Phase 2 N=647 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Phase 2 N=181 A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Major Pathologic Response (MPR) — 20.3 percentage of participants — p=<.0001
Phase 2 N=63 Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) Rate as Per Investigator Local Review Measured Using RECIST 1.1 of Patients at Week 12 — 23.3; 20.0 Percentage of participants